Neurosense Therapeutics Ltd. (NRSN) AI Stock Analysis

• Market Cap: $27.55M
• Dividend Yield: N/A
• Average Volume (3M): 324.40K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.66
• Revenue Growth: N/A
• EPS Growth: 31.09%
• Country: US
• Employees: 17
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.09
• Shares Outstanding: 24,602,406
• 10 Day Avg. Volume: 530,763
• 30 Day Avg. Volume: 324,396
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -1.85
• 1Y Price Target: $14.00
• Price Target Upside: 1020.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 30 Underperform
• Price Target: ―

Neurosense Therapeutics Ltd. faces substantial financial difficulties, including no revenue and negative equity, severely impacting its overall score. Technical indicators are neutral but do not offset financial weaknesses. The valuation is unattractive due to negative earnings and no dividend yield.

Positive Factors

Clinical Trials

NRSN plans to initiate the confirmatory Phase 3 trial for PrimeC for treating ALS.

Manufacturing

NRSN has completed the scale-up of its manufacturing process of PrimeC to commercial scale.

Product Development

NeuroSense is continuing to progress the development of PrimeC for treating amyotrophic lateral sclerosis (ALS), and previously received feedback from the FDA regarding the Phase trial 3 design for PrimeC.

Negative Factors

Financial Constraints

While the data previously generated for PrimeC has been promising, the company still has capital constraints, including its 'baby shelf' limitations, which will make it difficult to raise sufficient capital to fully finance the Phase 3 trial.

Funding Uncertainty

NeuroSense still has not signed a definitive agreement with the previously-undisclosed partner to fund PrimeC’s Phase 3 program and commercialization.

Regulatory Challenges

The company received negative feedback from Health Canada regarding an accelerated approval pathway for PrimeC for treating ALS.

Neurosense Therapeutics Ltd. Business Overview & Revenue Model

Company Description

Neurosense Therapeutics Ltd. (NRSN) is a biotechnology company focused on developing treatments for neurodegenerative diseases. The company operates primarily in the biopharmaceutical sector, leveraging advanced scientific research and innovative technologies to create novel therapeutic solutions. Its core product candidates target conditions such as amyotrophic lateral sclerosis (ALS) and other severe neurological disorders, aiming to improve patient outcomes and quality of life.

How the Company Makes Money

Neurosense Therapeutics Ltd. generates revenue primarily through funding and partnerships related to its research and development activities. The company may secure revenue from licensing agreements, where larger pharmaceutical companies pay upfront fees, milestone payments, and royalties for the rights to develop and commercialize its drug candidates. Additionally, Neurosense might receive government grants or private funding to support its research initiatives. As its products progress through clinical trials and towards market approval, the company may also enter into strategic collaborations that contribute to its financial growth.

Neurosense Therapeutics Ltd. Financial Statement Overview

Summary

Neurosense Therapeutics Ltd. has significant financial challenges, including a lack of revenue, consistent operational losses, a weak balance sheet, and cash flow management issues.

Income Statement

Neurosense Therapeutics Ltd. has no revenue streams, resulting in negative gross profit and net income over the years. The company consistently operates at a loss, with EBIT and EBITDA margins being negative. The absence of revenue and declining net income indicates significant challenges in achieving profitability.

Balance Sheet

The company has a weak balance sheet with negative stockholders' equity in recent years, indicating potential issues with financial stability. The debt-to-equity ratio cannot be calculated due to negative equity, emphasizing the need for improved financial structure. Total liabilities exceed total assets, posing a risk to financial solvency.

Cash Flow

Neurosense Therapeutics Ltd. is experiencing negative free cash flow, with operating cash flow consistently negative. The free cash flow growth is volatile with significant fluctuations, highlighting cash management challenges. The company relies heavily on financing activities to manage its cash flow requirements.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-22.00K	-97.00K	-89.00K	-3.00K	-3.00K
EBITDA	-13.28M	-9.88M	-9.64M	-13.38M	-2.88M	-2.83M
Net Income	-11.36M	-10.21M	-10.11M	-10.49M	-2.50M	-2.83M
Balance Sheet
Total Assets	984.00K	4.58M	3.18M	7.71M	11.43M	779.00K
Cash, Cash Equivalents and Short-Term Investments	344.00K	3.38M	2.64M	7.09M	11.06M	699.00K
Total Debt	19.00K	73.00K	142.00K	211.00K	1.83M	0.00
Total Liabilities	3.80M	1.99M	4.94M	2.09M	2.42M	120.00K
Stockholders Equity	-2.82M	2.58M	-1.87M	5.62M	9.01M	659.00K
Cash Flow
Free Cash Flow	0.00	-10.14M	-8.38M	-7.66M	-1.56M	-704.00K
Operating Cash Flow	0.00	-10.13M	-8.35M	-7.59M	-1.54M	-695.00K
Investing Cash Flow	0.00	1.00K	3.47M	-3.54M	-17.00K	-9.00K
Financing Cash Flow	0.00	10.91M	3.98M	3.69M	11.90M	508.00K

Neurosense Therapeutics Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.25
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRSN, the sentiment is Negative. The current price of 1.25 is below the 20-day moving average (MA) of 1.63, below the 50-day MA of 1.90, and below the 200-day MA of 1.33, indicating a bearish trend. The MACD of -0.21 indicates Positive momentum. The RSI at 36.36 is Neutral, neither overbought nor oversold. The STOCH value of 22.34 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NRSN.

Neurosense Therapeutics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.43B	-0.36	-45.45%	2.27%	22.98%	-2.34%
GBIO	47 Neutral	$27.15M	―	-85.45%	―	61.15%	54.71%
LTRN	45 Neutral	$47.99M	―	-75.66%	―	―	-13.72%
LGVN	45 Neutral	$10.33M	―	-167.57%	―	68.67%	85.44%
PASG	44 Neutral	$17.50M	―	-88.27%	―	―	32.57%
CGTX	41 Neutral	$80.82M	―	-219.68%	―	―	29.58%
NRSN	30 Underperform	$27.55M	―	-2880.11%	―	―	31.09%